Literature DB >> 17555721

Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine.

Aliza Werner-Seidler1, Rick Richardson.   

Abstract

BACKGROUND: D-cycloserine (DCS), a partial N-methyl-D-aspartate (NMDA) agonist, facilitates the extinction of conditioned fear in animals and promotes the efficacy of exposure-based therapies in humans. The current study examined whether pre-exposure to the antidepressant imipramine affects the enhancement of extinction by DCS.
METHODS: Twenty-nine rats were pre-exposed to saline, DCS, or imipramine for 14 days. The next day they were given five noise-shock pairings. The day after training, rats received six extinction trials and were then injected with DCS. At test the following day, freezing elicited by the noise was measured.
RESULTS: Rats pre-exposed to either DCS or imipramine exhibited more freezing at test than rats pre-exposed to saline.
CONCLUSIONS: Chronic exposure to either DCS or imipramine prevents the facilitating effect of DCS on extinction. This result suggests that DCS may not effectively enhance loss of fear in patients who are also being treated with antidepressants.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17555721     DOI: 10.1016/j.biopsych.2007.04.010

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  20 in total

Review 1.  Pharmacological enhancement of drug cue extinction learning: translational challenges.

Authors:  K M Kantak; B Á Nic Dhonnchadha
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

Review 2.  Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.

Authors:  Michael W Otto; M Alexandra Kredlow; Jasper A J Smits; Stefan G Hofmann; David F Tolin; Rianne A de Kleine; Agnes van Minnen; A Eden Evins; Mark H Pollack
Journal:  Biol Psychiatry       Date:  2015-09-25       Impact factor: 13.382

Review 3.  Generating new neurons to circumvent your fears: the role of IGF signaling.

Authors:  R C Agis-Balboa; A Fischer
Journal:  Cell Mol Life Sci       Date:  2013-03-30       Impact factor: 9.261

Review 4.  Mechanisms to medicines: elucidating neural and molecular substrates of fear extinction to identify novel treatments for anxiety disorders.

Authors:  Olena Bukalo; Courtney R Pinard; Andrew Holmes
Journal:  Br J Pharmacol       Date:  2014-07-23       Impact factor: 8.739

Review 5.  Pharmacological enhancement of fear reduction: preclinical models.

Authors:  Bronwyn M Graham; Julia M Langton; Rick Richardson
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Effects of low-dose D-serine on recognition and working memory in mice.

Authors:  Patricia Bado; Caroline Madeira; Charles Vargas-Lopes; Thiago C Moulin; Ana Paula Wasilewska-Sampaio; Luise Maretti; Ricardo V de Oliveira; Olavo B Amaral; Rogério Panizzutti
Journal:  Psychopharmacology (Berl)       Date:  2011-05-10       Impact factor: 4.530

Review 7.  Pharmacology of cognitive enhancers for exposure-based therapy of fear, anxiety and trauma-related disorders.

Authors:  N Singewald; C Schmuckermair; N Whittle; A Holmes; K J Ressler
Journal:  Pharmacol Ther       Date:  2014-12-27       Impact factor: 12.310

Review 8.  Cognitive enhancers for facilitating drug cue extinction: insights from animal models.

Authors:  Bríd Áine Nic Dhonnchadha; Kathleen M Kantak
Journal:  Pharmacol Biochem Behav       Date:  2011-02-02       Impact factor: 3.533

9.  D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial.

Authors:  JoAnn Difede; Judith Cukor; Katarzyna Wyka; Megan Olden; Hunter Hoffman; Francis S Lee; Margaret Altemus
Journal:  Neuropsychopharmacology       Date:  2013-11-12       Impact factor: 7.853

10.  A high-throughput clinical assay for testing drug facilitation of exposure therapy.

Authors:  Thomas L Rodebaugh; Cheri A Levinson; Eric J Lenze
Journal:  Depress Anxiety       Date:  2013-01-02       Impact factor: 6.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.